Expertise in
3
conditions

Sylvain Manfredi

Dijon, FR 
Expertise in
3
conditions
Dijon, FR 

Overview

Sylvain Manfredi practices practicing medicine in Dijon, France.

Mr. Manfredi is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Neuroendocrine Tumor, Liver Cancer, Colonoscopy, and Pancreaticoduodenectomy.

He is actively involved in clinical research, co-authoring 104 peer reviewed articles and participating in 12 clinical trials.

Gender

Male

Locations

Dijon, France
Other Locations
Bourgogne, France
2 Rue Henri Le Guilloux, 35033 Rennes Cedex 9, Rennes, 35033, France
Nantes, France
CHU Saint Louis, APHP
Paris, France
Lyon, France
CHRU de Tours
Tours, France
CHU St Etienne, Saint-etienne, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) of FOLFIRINOX Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yo. or Older) With a Metastatic Pancreatic Adenocarcinoma.
Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) of FOLFIRINOX Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yo. or Older) With a Metastatic Pancreatic Adenocarcinoma.
Enrollment Status: Completed
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drugs: Oxaliplatine, Folinic acid, Irinotecan, 5-FU
Study Phase: Phase 2
Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening, in First Degree Relatives of Patients With Colorectal Neoplasia: a Prospective Randomized Study.
Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening, in First Degree Relatives of Patients With Colorectal Neoplasia: a Prospective Randomized Study.
Enrollment Status: Completed
Publish Date: February 27, 2026
Intervention Type: Diagnostic test, Procedure
A Prospective, Post Approval, Multiple Centre, Open-Label, Non-Interventional, Registry Study to Evaluate Effectiveness of TheraSphere® in Clinical Practice in France
A Prospective, Post Approval, Multiple Centre, Open-Label, Non-Interventional, Registry Study to Evaluate Effectiveness of TheraSphere® in Clinical Practice in France
Enrollment Status: Completed
Publish Date: July 23, 2025
Intervention Type: Device
Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study
Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
Randomized Phase II Study Comparing 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI Followed by Two Months of Gemcitabine+Nab-paclitaxel, in Metastatic Pancreatic Cancer
Randomized Phase II Study Comparing 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI Followed by Two Months of Gemcitabine+Nab-paclitaxel, in Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drugs: Irinotecan Liposomal Injection, 5-FU/LV, Nab-Paclitaxel, Gemcitabine
Study Phase: Phase 2
Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable : a Multicentre Prospective Cohort
Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable : a Multicentre Prospective Cohort
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Other
Study Phase: Not Applicable
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: FOLFIRINOX, LV5FU2, FOLFIRI.3, Gemcitabine
Study Phase: Phase 2
Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers
Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
Enrollment Status: Unknown
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drugs: Ramucirumab, Paclitaxel
Study Phase: Phase 2
Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
Cohorte Non Interventionnelle Ambispective Nationale Multicentrique de Patients Suivis Pour Cancer et infectés Par le SARS-CoV-2
Enrollment Status: Completed
Publish Date: April 04, 2022
View 9 Less Clinical Trials

104 Total Publications

Response.
Response.
Journal: Gastrointestinal endoscopy
Published: April 30, 2026

Frequently Asked Questions about Sylvain Manfredi

Is Sylvain Manfredi a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Sylvain Manfredi is classified as an Advanced expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sylvain Manfredi participate in research or clinical trials?

Yes. Sylvain Manfredi has published 104 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Sylvain Manfredi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Manfredi's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile